{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T18:33:43Z","timestamp":1776450823659,"version":"3.51.2"},"reference-count":4,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,30]]},"DOI":"10.7759\/cureus.61364","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T13:45:46Z","timestamp":1717076746000},"source":"Crossref","is-referenced-by-count":2,"title":["An Unexpected Phenomenon: A Case of Citalopram-Induced Dyskinesia"],"prefix":"10.7759","author":[{"given":"Fabienne J","family":"Jean","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Poulose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v57n1002","article-title":"Movement disorders associated with the serotonin selective reuptake inhibitors","volume":"57","author":"Leo RJ","year":"1996","unstructured":"Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry. 1996, 57:449-54. 10.4088\/jcp.v57n1002","journal-title":"J Clin Psychiatry"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2006.08.004","article-title":"Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission","volume":"113","author":"Alex KD","year":"2007","unstructured":"Alex KD, Pehek EA. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther. 2007, 113:296-320. 10.1016\/j.pharmthera.2006.08.004","journal-title":"Pharmacol Ther"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852917000621","article-title":"Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less \"go\" and more \"stop\" from the motor striatum for robust therapeutic effects","volume":"23","author":"Stahl SM","year":"2018","unstructured":"Stahl SM. Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less \"go\" and more \"stop\" from the motor striatum for robust therapeutic effects. CNS Spectr. 2018, 23:1-6. 10.1017\/S1092852917000621","journal-title":"CNS Spectr"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0874-x","article-title":"Treatment of tardive dyskinesia: A general overview with focus on the vesicular monoamine transporter 2 inhibitors","volume":"78","author":"Niemann N","year":"2018","unstructured":"Niemann N, Jankovic J. Treatment of tardive dyskinesia: A general overview with focus on the vesicular monoamine transporter 2 inhibitors. Drugs. 2018, 78:525-41. 10.1007\/s40265-018-0874-x","journal-title":"Drugs"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/250934-an-unexpected-phenomenon-a-case-of-citalopram-induced-dyskinesia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T13:45:49Z","timestamp":1717076749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/250934-an-unexpected-phenomenon-a-case-of-citalopram-induced-dyskinesia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":4,"URL":"https:\/\/doi.org\/10.7759\/cureus.61364","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,30]]}}}